Skip to content

Disc Medicine IRON Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
17.8×+0.5×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
13.6×-4.3×
Beam Therapeutics logo
Beam TherapeuticsBEAM
17×+8.2×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
2.9×+1.0×

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on the most recent quarter.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's quick ratio?
Disc Medicine (IRON) reported quick ratio of 24× in Q1 2026.
How has Disc Medicine's quick ratio changed year-over-year?
Disc Medicine's quick ratio decreased by 36.3% year-over-year, from 37.7× to 24×.
What is the long-term trend for Disc Medicine's quick ratio?
Over 5 years (2020 to 2025), Disc Medicine's quick ratio has grown at a 155.0% compound annual growth rate (CAGR), from 0.2× to 21.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.